Xy­lo­Cor finds new back­ing to push re­gen­er­a­tive heart dis­ease gene ther­a­py deep­er in­to the clin­ic

Xy­lo­Cor Ther­a­peu­tics is one step clos­er to ac­com­plish­ing the tough task of de­liv­er­ing gene ther­a­pies straight in­to the heart for coro­nary artery dis­ease.

Three years af­ter its first fundraise, Xy­lo­Cor has raised an ad­di­tion­al $22.6 mil­lion in a Se­ries A ex­ten­sion, with the goal of ex­pand­ing its lead pro­gram in­to fur­ther tri­als. Called XC001, the pro­gram is cur­rent­ly be­ing stud­ied in pa­tients who have re­frac­to­ry angi­na, and Xy­lo­Cor wants to study its use as a po­ten­tial ad­junc­tive for those un­der­go­ing by­pass surgery.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.